Randomized trial reveals targeting arginine metabolism reduces bone metastasis in ARID1A-deficient triple negative breast cancer, suggesting new treatment approaches.
Key Points
The aim is to understand the impact of ARID1A deficiency on bone metastasis and explore arginine metabolism as a potential therapeutic target.
Analyzed incidence of bone metastasis in ARID1A-mutated TNBC patients.
Investigated the role of arginine metabolic pathway and its enzymes in promoting PMN-MDSC expansion in bone marrow.
Targeted ARG2 and ODC1 enzymes to assess their effect on reducing bone metastasis.
ARID1A-deficient TNBC patients show a higher incidence of bone metastasis.
Inhibition of ARG2 and ODC1 significantly reduces bone metastasis in ARID1A-deficient models.
Arginine metabolism is linked to the expansion of PMN-MDSCs in the bone marrow.